Small Intestinal Bacterial Overgrowth Syndrome

Okuniewicz, Robert; Moos, Łukasz; Brzoza, Zenon

doi:10.21307/pm-2021.60.3.16

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An analysis of fluoroquinolones revealed that they were characterized by growing resistance and demonstrated a significant deleterious impact on gastrointestinal microbiota. Hence, they should be used in a limited way because uncontrolled and often repeated therapeutic cycles with these drugs in the treatment of urinary tract infections are a selection factor for drug-resistant mutants [10][11][12]. In this situation, eravacycline was a better choice for treating complicated urinary tract infections.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

et al. 2023

View full text Add to dashboard Cite

Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. For this reason, it may be an alternative to treating critical infections of this etiology. We aimed to assess the in vitro effectiveness of eravacycline to carbapenemase-producing Gram-negative bacilli clinical isolates identified in hospitals in Łódź, Poland. We analyzed 102 strains producing KPC, MBL, OXA-48, GES, and other carbapenemases. Eravacycline susceptibility was determined following the EUCAST guidelines. The highest susceptibility was found in KPC (73%) and MBL (59%) strains. Our results confirmed in vitro the efficacy of this drug against carbapenem-resistant strains. However, eravacycline has been indicated only for treating complicated intra-abdominal infections, significantly limiting its use. This aspect should be further explored to expand the indications for using eravacycline supported by evidence-based medicine. Eravacycline is one of the drugs that could play a role in reducing the spread of multidrug-resistant microorganisms.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[25] Doboru terapii dokonuje się biorąc pod uwagę nasilenie objawów i potencjalny charakter patogenu rozrastającego się w nadmiarze. [32] Pomimo skutecznej antybiotykoterapii częstość nawrotów jest wciąż dosyć wysoka. [25,27] Skupienie uwagi jedynie na terapii farmakologicznej może być zgubne, gdyż SIBO jest problemem złożonym, a terapia bez modyfikacji stylu życia i przyzwyczajeń dietetycznych może nasilać dysfunkcje jelitowe.…”

Section: Sibo a Choroby O Charakterze Manifestacji Skórnejunclassified

SIBO - the present knowledge within the contekst of clinical dependencies and therapy

Marta

LESZCZ²,

BIEŃKO

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: The gut microbiome is an integral part of the body, and the eubiosis conditio significantly influences homeostasis. Small intestinal bacterial overgrowth (SIBO) is connected with an increased numer of bacteria, it causes gastrointestinal symptoms. The main symptoms are abdominal pain, bloating and diarrhea. SIBO correlates with the occurrence of other chronic diseases. The basis of treatment are antibiotics. There are also scientific reports on supplementing pharmacological therapy with dietary management. Objective: The purpose of this paper is to review the current knowledge on the bacterial overgrowth of the small intestine. Particular attention took notice of to the relationship between SIBO and other chronic diseases as well as potential and applied treatments. Material and methods: The review includes publications published in 2020-2023 and certain works published earlier, in the years 2008-2017. Data were collected using PubMed, ScienceDirect i Google Scholar. Results: Small intestinal bacterial overgrowth is heterogeneous disorder. Its symptoms are nonspecific. SIBO is related to several different diseases and corresponds with them. Empirical treatment consists in administration of antibiotics. Supplementing therapy with alternative methods for example probiotic and diet therapy promotes success in treating. Conclusions: The lack of standarized therapeutic menagment and focused on bacterial eradication only approach makes, SIBO is recurrent ailment. More research is needed. The important thing is holistic approach on etiology, pathogenesis and therapy.

show abstract

Small Intestinal Bacterial Overgrowth Syndrome

Cited by 2 publications

References 30 publications

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland

SIBO - the present knowledge within the contekst of clinical dependencies and therapy

Contact Info

Product

Resources

About